APA (7th ed.) Citation

Chang Chen, Chang Chen, Yi Zhang, Yi Zhang, Jianying Huang, Jianying Huang, . . . Xinghuan Wang. (2021). Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Chang Chen, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Frontiers Media S.A., 2021.

MLA (9th ed.) Citation

Chang Chen, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Frontiers Media S.A., 2021.